PCSK9与系统性红斑狼疮患者发生动脉粥样硬化的关系
The Relationship between PCSK9 and the Occurrence of Atherosclerosis in Patients with Systemic Lupus Erythematosus
DOI: 10.12677/jcpm.2026.51069, PDF,    科研立项经费支持
作者: 葛 娜*：济宁医学院临床医学院(附属医院)，山东 济宁；姜承瑞#：济宁市第一人民医院风湿免疫科，山东 济宁
关键词: PCSK9；系统性红斑狼疮；心血管疾病；动脉粥样硬化；PCSK9； Systemic Lupus Erythematosus (SLE)； Cardiovascular Disease； Atherosclerosis (AS)
摘要: 系统性红斑狼疮(systemic lupus erythematosus, SLE)患者心血管疾病风险显著增高，其动脉粥样硬化发生早、进展快，传统危险因素无法完全解释。前蛋白转化酶枯草溶菌素9 (proprotein convertases subtilisin/kexin type 9, PCSK9)作为调控低密度脂蛋白胆固醇(LDL-C)代谢的关键蛋白酶，不仅通过降解肝细胞LDL受体升高血脂，还具有调节炎症、免疫应答、细胞自噬等多重非脂质代谢功能。本研究旨在探讨SLE合并动脉粥样硬化的机制及其与PCSK9的关系，以期为SLE患者合并颈动脉硬化的早期诊断与治疗提供依据。
Abstract: Systemic lupus erythematosus (SLE) patients have a significantly increased risk of cardiovascular disease, with accelerated and accelerated atherogenesis that cannot be fully explained by traditional risk factors. Proprotein convertases subtilisin/kexin type 9 (PCSK9), a key protease that regulates low-density lipoprotein cholesterol (LDL-C) metabolism, not only elevates lipid levels by promoting degradation of hepatic LDL receptors but also exerts multiple non-lipid metabolic functions, including regulation of inflammation, immune response, and autophagy. The aim of this study is to explore the mechanisms of SLE with comorbid atherosclerosis and its relationship with PCSK9, in order to provide a basis for the early diagnosis and treatment of carotid atherosclerosis in patients with SLE.
文章引用：葛娜, 姜承瑞. PCSK9与系统性红斑狼疮患者发生动脉粥样硬化的关系[J]. 临床个性化医学, 2026, 5(1): 500-507. https://doi.org/10.12677/jcpm.2026.51069

参考文献

[1] Nor, M.A., Ogedegbe, O.J., Barbarawi, A., Ali, A.I., Sheikh, I.M., Yussuf, F.M., et al. (2023) Systemic Lupus Erythematosus and Cardiovascular Diseases: A Systematic Review. Cureus, 15, e39284. [Google Scholar] [CrossRef] [PubMed]
[2] Li, M., Li, C., Cao, M., Lu, K., Wu, C., Wang, J., et al. (2024) Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-Based Study. Science Bulletin, 69, 3089-3097. [Google Scholar] [CrossRef] [PubMed]
[3] Atzeni, F., Rodríguez-Pintó, I. and Cervera, R. (2024) Cardiovascular Disease Risk in Systemic Lupus Erythematous: Certainties and Controversies. Autoimmunity Reviews, 23, Article ID: 103646. [Google Scholar] [CrossRef] [PubMed]
[4] Ambler, W.G. and Kaplan, M.J. (2024) Vascular Damage in Systemic Lupus Erythematosus. Nature Reviews Nephrology, 20, 251-265. [Google Scholar] [CrossRef] [PubMed]
[5] Roman, M.J., Shanker, B., Davis, A., Lockshin, M.D., Sammaritano, L., Simantov, R., et al. (2003) Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus. New England Journal of Medicine, 349, 2399-2406. [Google Scholar] [CrossRef] [PubMed]
[6] Weber, B. and Liao, K.P. (2023) Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis. Rheumatic Disease Clinics of North America, 49, 165-178. [Google Scholar] [CrossRef] [PubMed]
[7] Myasoedova, E., Davis, J.M., Roger, V.L., Achenbach, S.J. and Crowson, C.S. (2021) Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in the 2000s: A Population-Based Cohort Study. The Journal of Rheumatology, 48, 1379-1387. [Google Scholar] [CrossRef] [PubMed]
[8] Yen, E.Y. and Singh, R.R. (2018) Brief Report: Lupus—An Unrecognized Leading Cause of Death in Young Females: A Population‐Based Study Using Nationwide Death Certificates, 2000-2015. Arthritis & Rheumatology, 70, 1251-1255. [Google Scholar] [CrossRef] [PubMed]
[9] Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., Berger, R.D., et al. (2001) Traditional Framingham Risk Factors Fail to Fully Account for Accelerated Atherosclerosis in Systemic Lupus Erythematosus. Arthritis & Rheumatism, 44, 2331-2337. [Google Scholar] [CrossRef] [PubMed]
[10] Manzi, S., Meilahn, E.N., Rairie, J.E., Conte, C.G., Medsger, T.A., Jansen-McWilliams, L., et al. (1997) Age-Specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study. American Journal of Epidemiology, 145, 408-415. [Google Scholar] [CrossRef] [PubMed]
[11] Bruce, I.N. (2005) ‘Not Only…but Also’: Factors That Contribute to Accelerated Atherosclerosis and Premature Coronary Heart Disease in Systemic Lupus Erythematosus. Rheumatology, 44, 1492-1502. [Google Scholar] [CrossRef] [PubMed]
[12] Schanberg, L.E., Sandborg, C., Barnhart, H.X., Ardoin, S.P., Yow, E., Evans, G.W., et al. (2011) Use of Atorvastatin in Systemic Lupus Erythematosus in Children and Adolescents. Arthritis & Rheumatism, 64, 285-296. [Google Scholar] [CrossRef] [PubMed]
[13] Tselios, K., Koumaras, C., Gladman, D.D. and Urowitz, M.B. (2016) Dyslipidemia in Systemic Lupus Erythematosus: Just Another Comorbidity? Seminars in Arthritis and Rheumatism, 45, 604-610. [Google Scholar] [CrossRef] [PubMed]
[14] Sun, C., Qin, W., Zhang, Y., Wu, Y., Li, Q., Liu, M., et al. (2017) Prevalence and Risk of Metabolic Syndrome in Patients with Systemic Lupus Erythematosus: A Meta‐Analysis. International Journal of Rheumatic Diseases, 20, 917-928. [Google Scholar] [CrossRef] [PubMed]
[15] Apostolopoulos, D., Vincent, F., Hoi, A. and Morand, E. (2020) Associations of Metabolic Syndrome in SLE. Lupus Science & Medicine, 7, e000436. [Google Scholar] [CrossRef] [PubMed]
[16] Ronda, N., Favari, E., Borghi, M.O., Ingegnoli, F., Gerosa, M., Chighizola, C., et al. (2014) Impaired Serum Cholesterol Efflux Capacity in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 73, 609-615. [Google Scholar] [CrossRef] [PubMed]
[17] Tyrrell, P.N., Beyene, J., Benseler, S.M., Sarkissian, T. and Silverman, E.D. (2007) Predictors of Lipid Abnormalities in Children with New-Onset Systemic Lupus Erythematosus. The Journal of Rheumatology, 34, 2112-2119.
[18] Magder, L.S. and Petri, M. (2012) Incidence of and Risk Factors for Adverse Cardiovascular Events among Patients with Systemic Lupus Erythematosus. American Journal of Epidemiology, 176, 708-719. [Google Scholar] [CrossRef] [PubMed]
[19] Nikpour, M., Urowitz, M.B., Ibanez, D., Harvey, P.J. and Gladman, D.D. (2011) Importance of Cumulative Exposure to Elevated Cholesterol and Blood Pressure in Development of Atherosclerotic Coronary Artery Disease in Systemic Lupus Erythematosus: A Prospective Proof-Of-Concept Cohort Study. Arthritis Research & Therapy, 13, R156. [Google Scholar] [CrossRef] [PubMed]
[20] Kandane-Rathnayake, R., Golder, V., Louthrenoo, W., Chen, Y., Cho, J., Lateef, A., et al. (2022) Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study. The Lancet Rheumatology, 4, e822-e830. [Google Scholar] [CrossRef] [PubMed]
[21] Ugarte-Gil, M.F., Mak, A., Leong, J., Dharmadhikari, B., Kow, N.Y., Reátegui-Sokolova, C., et al. (2021) Impact of Glucocorticoids on the Incidence of Lupus-Related Major Organ Damage: A Systematic Literature Review and Meta-Regression Analysis of Longitudinal Observational Studies. Lupus Science & Medicine, 8, e000590. [Google Scholar] [CrossRef] [PubMed]
[22] Billi, A.C., Ma, F., Plazyo, O., Gharaee-Kermani, M., Wasikowski, R., Hile, G.A., et al. (2022) Nonlesional Lupus Skin Contributes to Inflammatory Education of Myeloid Cells and Primes for Cutaneous Inflammation. Science Translational Medicine, 14, eabn2263. [Google Scholar] [CrossRef] [PubMed]
[23] Dunlap, G.S., Billi, A.C., Xing, X., Ma, F., Maz, M.P., Tsoi, L.C., et al. (2022) Single-Cell Transcriptomics Reveals Distinct Effector Profiles of Infiltrating T Cells in Lupus Skin and Kidney. JCI Insight, 7, e156341. [Google Scholar] [CrossRef] [PubMed]
[24] Perez, R.K., Gordon, M.G., Subramaniam, M., Kim, M.C., Hartoularos, G.C., Targ, S., et al. (2022) Single-Cell RNA-Seq Reveals Cell Type–specific Molecular and Genetic Associations to Lupus. Science, 376, eabf1970. [Google Scholar] [CrossRef] [PubMed]
[25] Frostegård, J. (2022) Systemic Lupus Erythematosus and Cardiovascular Disease. Journal of Internal Medicine, 293, 48-62. [Google Scholar] [CrossRef] [PubMed]
[26] Farmaki, P., Damaskos, C., Garmpis, N., Garmpi, A., Savvanis, S. and Diamantis, E. (2020) PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes. Current Drug Discovery Technologies, 17, 138-146. [Google Scholar] [CrossRef] [PubMed]
[27] 李东泽, 赵继义. PCSK9通过非血脂途径致动脉粥样硬化的研究进展[J] .中国临床药理学与治疗学, 2025, 30(10): 1400-1407.
[28] Ugovšek, S., Zupan, J., Rehberger Likozar, A. and Sebestjen, M. (2021) Influence of Lipid-Lowering Drugs on Inflammation: What Is Yet to Be Done? Archives of Medical Science, 18, 855-869. [Google Scholar] [CrossRef] [PubMed]
[29] Barale, C., Melchionda, E., Morotti, A. and Russo, I. (2021) PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences, 22, Article 5880. [Google Scholar] [CrossRef] [PubMed]
[30] Ding, Z., Liu, S., Wang, X., Deng, X., Fan, Y., Sun, C., et al. (2015) Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and along the Mouse Aorta. Antioxidants & Redox Signaling, 22, 760-771. [Google Scholar] [CrossRef] [PubMed]
[31] Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., et al. (2024) Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): From Bench to Bedside. Signal Transduction and Targeted Therapy, 9, Article No. 13. [Google Scholar] [CrossRef] [PubMed]
[32] Jukema, J.W., Szarek, M., Zijlstra, L.E., de Silva, H.A., Bhatt, D.L., Bittner, V.A., et al. (2019) Alirocumab in Patients with Polyvascular Disease and Recent Acute Coronary Syndrome. Journal of the American College of Cardiology, 74, 1167-1176. [Google Scholar] [CrossRef] [PubMed]
[33] Erviti, J., Wright, J., Bassett, K., Ben-Eltriki, M., Jauca, C., Saiz, L.C., et al. (2022) Restoring Mortality Data in the FOURIER Cardiovascular Outcomes Trial of Evolocumab in Patients with Cardiovascular Disease: A Reanalysis Based on Regulatory Data. BMJ Open, 12, e060172. [Google Scholar] [CrossRef] [PubMed]
[34] Frostegård, J. (2021) The Role of PCSK9 in Inflammation, Immunity, and Autoimmune Diseases. Expert Review of Clinical Immunology, 18, 67-74. [Google Scholar] [CrossRef] [PubMed]
[35] Xie, W., Li, J., Du, H. and Xia, J. (2023) Causal Relationship between PCSK9 Inhibitor and Autoimmune Diseases: A Drug Target Mendelian Randomization Study. Arthritis Research & Therapy, 25, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[36] Koskinas, K.C., Windecker, S., Pedrazzini, G., Mueller, C., Cook, S., Matter, C.M., et al. (2019) Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 74, 2452-2462. [Google Scholar] [CrossRef] [PubMed]
[37] 梁日明, 吴国新, 张健瑜, 等. 依洛尤单抗对急性心肌梗死患者血浆中PCSK9、LDL-C和LP(a)的影响作用[J]. 齐齐哈尔医学院学报, 2022, 43(23): 2235-2238.
[38] Gouni-Berthold, I. and Berthold, H. (2014) PCSK9 Antibodies for the Treatment of Hypercholesterolemia. Nutrients, 6, 5517-5533. [Google Scholar] [CrossRef] [PubMed]
[39] 李沁瑶, 胥崟崧. PCSK9抑制剂与自身免疫性疾病之间的关联: 孟德尔随机化研究[J]. 今日药学, 2024, 34(6): 419-426.
[40] Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. [Google Scholar] [CrossRef] [PubMed]
[41] 王增武, 郭远林. 中国血脂管理指南(基层版2024年) [J]. 临床心血管病杂志, 2024, 40(4): 249-256.
[42] 安徽省医疗保障局安徽省人力资源和社会保障厅关于执行《国家基本医疗保险、工伤保险和生育保险药品目录(2021年)》的通知[J]. 安徽省人民政府公报, 2022(1): 35-36.
[43] Wang, Q., Zheng, B., Chen, P. and Lei, Y. (2022) Leptin and PCSK9 Concentrations Are Associated with Vascular Endothelial Cytokines in Patients with Stable Coronary Heart Disease. Open Medicine, 17, 185-190. [Google Scholar] [CrossRef] [PubMed]
[44] Fang, C., Luo, T., Chen, X. and Lin, L. (2018) Elevated Level of Serum PCSK9 in Patients with Systemic Lupus Erythematosus. Chinese Journal of Cellular and Molecular Immunology, 34, 541-545.
[45] Oliveira, C.B. and Kaplan, M.J. (2022) Cardiovascular Disease Risk and Pathogenesis in Systemic Lupus Erythematosus. Seminars in Immunopathology, 44, 309-324. [Google Scholar] [CrossRef] [PubMed]
[46] Guo, Y., Tang, Z., Yan, B., Yin, H., Tai, S., Peng, J., et al. (2022) PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, 67-86. [Google Scholar] [CrossRef] [PubMed]
[47] Shimada, Y.J. and Cannon, C.P. (2015) PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors: Past, Present, and the Future. European Heart Journal, 36, 2415-2424. [Google Scholar] [CrossRef] [PubMed]